AstraZeneca PLC ADR
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $13,565,000 | $12,938,000 | $12,679,000 | $12,024,000 |
Gross Profit | 10,484,000 | 10,755,000 | 10,461,000 | 9,716,000 |
EBITDA | 4,102,000 | 4,119,000 | 4,565,000 | 2,179,000 |
EBIT | 2,285,000 | 2,840,000 | 3,310,000 | 1,305,000 |
Net Income | 1,429,000 | 1,927,000 | 2,179,000 | 960,000 |
Net Change In Cash | 13,565,000 | 12,938,000 | 12,679,000 | 12,024,000 |
Free Cash Flow | 2,025,000 | 2,417,000 | 881,000 | 1,434,000 |
Cash | 4,797,000 | 6,916,000 | 7,841,000 | 5,840,000 |
Basic Shares | 1,560,000 | 1,560,000 | 1,560,000 | 1,561,000 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $45,811,000 | $44,351,000 | $37,417,000 | $26,617,000 |
Gross Profit | 37,771,000 | 31,960,000 | 24,980,000 | 21,318,000 |
EBITDA | 13,422,000 | 9,085,000 | 5,113,000 | 8,084,000 |
EBIT | 8,488,000 | 3,831,000 | 1,011,000 | 5,188,000 |
Net Income | 5,955,000 | 3,288,000 | 112,000 | 3,196,000 |
Net Change In Cash | 45,811,000 | 44,351,000 | 37,417,000 | 26,617,000 |
Free Cash Flow | 6,567,000 | 7,237,000 | 3,763,000 | 2,193,000 |
Cash | 5,840,000 | 6,166,000 | 6,329,000 | 7,832,000 |
Basic Shares | 1,562,000 | 1,560,000 | 1,427,000 | 1,313,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.45 |
2024-06-30 | $0.99 |
2024-03-31 | $1.03 |
2023-12-31 | $0.73 |
